BiotechTube

ALLO-647 + Fludarabine + Cyclophosphamide

Phase 1/2Active
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Conditions

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Trial Timeline

May 21, 2020 → May 1, 2029

NCT ID
NCT04416984

About ALLO-647 + Fludarabine + Cyclophosphamide

ALLO-647 + Fludarabine + Cyclophosphamide is a phase 1/2 stage product being developed by Allogene Therapeutics for Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT04416984. Target conditions include Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma.

What happened to similar drugs?

2 of 20 similar drugs in Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma were approved

Approved (2) Terminated (2) Active (16)
✅Acalabrutinib capsuleAstraZenecaApproved
✅Drug: Carfilzomib + Dexamethasone + Drug: Carfilzomib + Lenalidomide + DexamethasoneAmgenApproved
🔄CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
🔄AZD0120 + Daratumumab + Carfilzomib + Dexamethasone + Bortezomib + PomalidomideAstraZenecaPhase 3

Hype Score Breakdown

Clinical
9
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT05714345Phase 2Terminated
NCT05000450Phase 1/2Terminated
NCT04696731Phase 1Active
NCT04416984Phase 1/2Active
NCT03939026Phase 1Completed

Competing Products

20 competing products in Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

See all competitors
ProductCompanyStageHype Score
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-2736ModernaPhase 1
0
mRNA-2808ModernaPhase 2
0
mRNA-2416ModernaPhase 2
0
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
agenT-797MiNK TherapeuticsPhase 1
19
VIP152 + BTKiVincerx PharmaPhase 1
11
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
25
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
AC220Daiichi SankyoPhase 1
29
Valemetostat TosylateDaiichi SankyoPhase 2
39
LinsitinibAstellas PharmaPhase 2
35
AGS67EAstellas PharmaPhase 1
29
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
39
LenvatinibEisaiPhase 2
35
TazemetostatEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
Eribulin mesylateEisaiPhase 2
35
ME-401Kyowa KirinPhase 1
29
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6Kyowa KirinPhase 1
36